QR code

No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials

Remdesivir (RDV) is a broad-spectrum nucleotide analog prodrug approved for the treatment of COVID-19 in hospitalized and non-hospitalized patients with clinical benefit demonstrated in multiple Phase 3 trials. Here we present SARS-CoV-2 resistance analyses from the Phase 3 SIMPLE clinical studies e...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Charlotte Hedskog, Christoph D. Spinner, Ulrike Protzer, Dieter Hoffmann, Chunkyu Ko, Robert L. Gottlieb, Medhat Askar, Meta Roestenberg, Jutte J. C. de Vries, Ellen C. Carbo, Ross Martin, Jiani Li, Dong Han, Lauren Rodriguez, Aiyappa Parvangada, Jason K. Perry, Ricard Ferrer, Andrés Antón, Cristina Andrés, Vanessa Casares, Huldrych F. Günthard, Michael Huber, Grace A. McComsey, Navid Sadri, Judith A. Aberg, Harm van Bakel, Danielle P. Porter
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: MDPI AG 2024-03-01
Reeks:Viruses
Onderwerpen:
remdesivir
SARS-CoV-2
resistance
genotyping
phenotyping
Nsp12
Online toegang:https://www.mdpi.com/1999-4915/16/4/546
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items